Tranexamic acid: a new option for heavy menstrual bleeding.
Heavy menstrual bleeding, or menorrhagia, af ects approximately one-third of women. Treatments have included nonsteroidal anti-inflammatories and oral contraceptives, although neither is approved by the Food and Drug Administration (FDA) specifically for this use. Lysteda® (tranexamic acid) has recently been approved as a treatment for heavy menstrual bleeding. This article gives a background on menorrhagia and describes treatment with tranexamic acid, including its implications for nurses.
Jeanne M
JM
Wilton
D000933:Antifibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017277:Drug Approval; D005260:Female; D006801:Humans; D008595:Menorrhagia / Q000188:drug therapy* / Q000451:nursing; D014148:Tranexamic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D000933:Antifibrinolytic Agents; D014148:Tranexamic Acid